Torell, Agnes
Stockfelt, Marit
Blennow, Kaj
Zetterberg, Henrik
Akhter, Tansim
Leonard, Dag
Rönnblom, Lars
Pihl, Sofia
Saleh, Muna
Sjöwall, Christopher
Strevens, Helena
Jönsen, Andreas
Bengtsson, Anders A.
Trysberg, Estelle
Majczuk Sennström, Maria
Zickert, Agneta
Svenungsson, Elisabet
Gunnarsson, Iva
Bylund, Johan
Jacobsson, Bo
Rudin, Anna
Lundell, Anna-Carin
Funding for this research was provided by:
The Swedish Rheumatism Association
The Gothenburg Society of Medicine
The Swedish Society of Medicine
The Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement
Foundation of Ingegerd Johansson
The Swedish Research Council
Foundation of IngaBritt and Arne Lundberg
Foundations of The King Gustaf V’s 80th Birthday found
Foundation of Ulla and Roland Gustafsson
Foundation of Nanna Svartz
Foundation of Rune and Ulla Amlöv
Foundation of Hjalmar Svensson
Foundation of Emil and Wera Cornell
University of Gothenburg
Article History
Received: 31 October 2023
Accepted: 1 March 2024
First Online: 9 March 2024
Declarations
:
: The study complies with the Declaration of Helsinki and was approved by the appropriate medical ethical committee, the regional ethics committee of Gothenburg (Dnr 404–18 and amendment Dnr 2020–05101 and Dnr 2022–01158-02). All participants signed an informed consent form.
: Not applicable.
: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant and at advisory boards for Acumen, ALZPath, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. LR has collaboration with Astra Zeneca, Bristol Myers Squibb (BMS), AMPEL Biosolutions, UCB and Bayer. ES has received a research grant from Merck and lecture honoraria from Janssen. The other authors declare no conflict of interest.